Immix Biopharma moved immediately after an interim clinical readout for NXC-201, reporting an 89% complete response rate among 45 patients with light-chain (AL) amyloidosis in its BCMA-targeted CAR-T Phase II NEXICART-2 trial. Minutes later, the company announced a $125 million offering. Immix said it is lining up a BLA submission next year, when it expects final study data. The sequence of interim efficacy disclosure followed by a financing highlights how quickly capital markets are responding to late-stage hematology signals. For CAR-T and amyloidosis investors, the complete response rate—while interim and cohort-size dependent—adds to the competitive landscape of cell therapies aiming to convert deep responses into regulatory submissions. J.P. Morgan underwrote the offering, pointing to continued institutional support for conditional-risk bets tied to near-term regulatory timelines.